Is Shukun Technology profitable in 2026?

No confirmed profitability. At its 2021 Hong Kong IPO filing, Shukun reported gross margins above 80% but accumulated net losses exceeding RMB 300 million over roughly two and a half years, and no audited financials confirming a turnaround have surfaced since (as of July 2026).

Who owns Shukun Technology?

Shukun is privately held and venture-backed. Its August 2021 Series D round, which valued it at RMB 9.407 billion (about $1.46B), included Goldman Sachs, Sequoia Capital China, ThunderSoft, CCB International, BOC International, Huagai Capital and China Creation Ventures as investors.

Could Chinese big tech AI replace Shukun Technology's diagnostic products?

Tencent, Baidu, Alibaba and JD had collectively shipped over 50 medical AI models in China by early 2025, per industry reporting. They still lack Shukun's device-level regulatory clearances, but that certification gap is a paperwork barrier, not a structural one.

Is Shukun Technology going public soon?

Shukun filed for a Hong Kong IPO in September to October 2021 with JPMorgan, BofA Securities and Bank of China International as sponsors, but Pitchbook lists that deal as Cancelled, and no relaunch had been confirmed as of July 2026 despite HK$292.3B raised in Hong Kong IPOs in 2025.

Who is Shukun Technology's biggest competitor?

Airdoc, another Beijing-founded medical-imaging AI firm, became the first Chinese medical AI company to list on HKEX (2251.HK) and reportedly received China's first NMPA AI medical-device license in January 2020, putting it ahead of Shukun on public-market validation as of 2024.

How many hospitals use Shukun Technology's products?

Shukun states more than 1,800 hospitals in China have adopted its DigitalDoc imaging-AI products, per the World Economic Forum's organization profile; this figure is company-sourced and not independently audited.

China · China

Shukun Technology

Beijing AI company selling NMPA-certified diagnostic imaging software to Chinese hospitals.

Losing its protection

Assessed 29 July 2026 · Evidence as of 29 July 2026

The structural protection is eroding.

On the recordSince 29 July 2026 · Checkable from mid-2027 · Every call on the record Checkpoint: Window closes for HKEX IPO relaunch at or above 2021 valuation

The call

Shukun sits inside China's certified-device club with real hospital lock-in, but its 2021 IPO never happened and bigger tech companies are working the same approval pipeline.

Shukun Technology makes AI software that doctors use to read medical images and diagnose diseases. The company has government approvals in China and Europe that are hard to get, but five other similar companies already have those same approvals, and now Tencent, Baidu, Alibaba, and JD.com are building their own medical AI tools with far more money and engineering power behind them. These tech giants only need paperwork approval to launch, not new technology, so Shukun's advantage could shrink fast. Watch whether Shukun can go public in Hong Kong in the next year or two, because staying private while competitors move forward would be a bad sign.

Why

AI pressure: Tencent Hunyuan, Baidu Lingyi, Alibaba Tongyi Renxin medical imaging models. Big tech medical models could match Shukun's diagnostic accuracy once certified, then undercut it on price and integration. Could AI do the core job? Only partly.

Bigger players: Tencent, Baidu, Alibaba, JD medical AI units. These four have shipped 50+ medical models combined and are racing through the same device approval pipeline that currently shields Shukun. Could a giant copy it? Probably.

What protects it. 17 NMPA Class III plus 10 EU MDR CE device approvals and 1,800+ hospitals already running its software.

What would change this call

Shukun relaunches its HKEX IPO within 6-12 months at or above the 2021 valuation. Would show fundamentals and investor confidence remain intact.
NMPA grants Class III approval to a Tencent, Baidu, or Alibaba medical-imaging model. Would show the regulatory moat protecting Shukun is starting to erode.
Shukun loses hospital tender renewals to a named big-tech rival in new bidding rounds. Would show installed-base customers are actually switching, not just staying by default.

Key numbers

17 NMPA Class III + 10 EU MDR CE approvals (2025-03-31)
1,800+ Chinese hospitals use DigitalDoc (n.d.)
$1.46B valuation set at 2021 Series D (2021-08-01)

Named risks

HKEX IPO stalled since 2021 despite Hong Kong's 2025-2026 listing boom of HK$292.3B. Severity: high
Commoditization risk from Chinese big-tech medical AI models shipping 50+ models by early 2025. Severity: high
Revenue and headcount figures conflict by 10 to 30x across sources with no audited financials. Severity: medium
Valuation figure of $1.46B is nearly five years old, unrefreshed by a new funding round. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Airdoc	losing to	Airdoc HKEX-listed as 2251.HK and got first China NMPA AI device license Jan 2020, ahead of Shukun's stalled IPO
Tencent, Baidu, Alibaba, JD	gaining on	Collectively shipped 50+ medical AI models in China by early 2025
Infervision	contesting	Beijing rival founded 2015, same AI-assisted radiology niche
Yizhun, Deepwise, Keya Medical	contesting	Beijing-area peers founded 2017 with comparable device certifications

Questions people ask

Is Shukun Technology profitable in 2026?: No confirmed profitability. At its 2021 Hong Kong IPO filing, Shukun reported gross margins above 80% but accumulated net losses exceeding RMB 300 million over roughly two and a half years, and no audited financials confirming a turnaround have surfaced since (as of July 2026).
Who owns Shukun Technology?: Shukun is privately held and venture-backed. Its August 2021 Series D round, which valued it at RMB 9.407 billion (about $1.46B), included Goldman Sachs, Sequoia Capital China, ThunderSoft, CCB International, BOC International, Huagai Capital and China Creation Ventures as investors.
Could Chinese big tech AI replace Shukun Technology's diagnostic products?: Tencent, Baidu, Alibaba and JD had collectively shipped over 50 medical AI models in China by early 2025, per industry reporting. They still lack Shukun's device-level regulatory clearances, but that certification gap is a paperwork barrier, not a structural one.
Is Shukun Technology going public soon?: Shukun filed for a Hong Kong IPO in September to October 2021 with JPMorgan, BofA Securities and Bank of China International as sponsors, but Pitchbook lists that deal as Cancelled, and no relaunch had been confirmed as of July 2026 despite HK$292.3B raised in Hong Kong IPOs in 2025.
Who is Shukun Technology's biggest competitor?: Airdoc, another Beijing-founded medical-imaging AI firm, became the first Chinese medical AI company to list on HKEX (2251.HK) and reportedly received China's first NMPA AI medical-device license in January 2020, putting it ahead of Shukun on public-market validation as of 2024.
How many hospitals use Shukun Technology's products?: Shukun states more than 1,800 hospitals in China have adopted its DigitalDoc imaging-AI products, per the World Economic Forum's organization profile; this figure is company-sourced and not independently audited.

Timeline

2026-07Pitchbook lists Shukun's HKEX IPO deal as Cancelled; no completed listing found
2025-04Senior-focused AI doctor product reportedly launched in Beijing (company-sourced)
2025-03-31Company reports holding 17 NMPA Class III and 10 EU MDR CE device approvals
2024-10Careverse CoronaryDoc launches in Japan via Clairvo Technologies partnership
2023-12-31Suzhou-area partnership reportedly quadruples CT screening volumes to 190,000
2021-10Shukun files HKEX IPO prospectus with JPMorgan, BofA, BOC International as sponsors
2021-08Series D round values Shukun at RMB 9.407 billion (about $1.46B)
2017-01Shukun founded in Beijing by Ma Chun'e

Revision history

29 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Meituan Shein Group Xiaomi Corporation